Vaccination against respiratory syncytial virus for adults over 60 is likely to be cost-effective by preventing illness, ...

A third COVID-19 vaccine will be available shortly as Novavax joins Pfizer/BioNTech and Moderna in targeting variants that ...

On August 22, Moderna announced that FDA approved ... On the same day, Pfizer and BioNTech also announced that they received approval for their sBLA for an updated composition of their Omicron ...

The Food and Drug Administration approved ... Both Pfizer and Moderna’s shots target the KP.2 COVID-19 variant—JN.1 is the parent variant of KP.2. The FDA in June asked vaccine makers to ...

Vaccination against respiratory syncytial virus for adults over 60 is likely cost-effective by preventing illness, hospitalizations, lost quality of life and deaths, according to new research.

Gov. Kathy Hochul recently announced the new COVID-19 vaccine for the 2024-2025 season is now available in New York State.

The FDA has approved an updated covid shot for everyone 6 months old and up, which renews a now-annual quandary for Americans ...

These vaccines are now available to adults 60 and older. In terms of dosage, the CDC recommends a single dose for individuals over 75.

What about the new COVID booster approved ... that RSV vaccines are not recommended annually like the flu vaccine, and one ...

The Hawaii Department of Health is recommending residents get updated flu and COVID-19 vaccines that are now available.

The FDA just signed off on new COVID vaccines, and pharmacies are taking appointments for people looking to catch up on those vaccines and others.

Vaccination against respiratory syncytial virus for adults over 60 is likely cost-effective by preventing illness, ...